Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 14 December 2025 - 16 December 2025

Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly and Company stock (NYSE: LLY) remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand. In early trading on Tuesday, Dec. 16, Eli Lilly shares hovered around the $1,050 area, after a year that included the company becoming the first drugmaker to reach a $1 trillion market value—a milestone that underscored how central Lilly’s metabolic franchise has become to investors.
16 December 2025
··
Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer’s latest outlook is setting the tone for how investors may view the drugmaker’s post-pandemic transition in 2026: steady underlying growth ambitions, but a near-term financial “air pocket” as COVID-19 revenue continues to shrink and several products face patent and exclusivity headwinds. On December 16, 2025, Pfizer issued its full-year 2026 guidance, projecting revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00—both ranges that came in below Wall Street expectations cited by major financial outlets covering the update. Business Wire+2Reuters+2 The market reaction has been measured. After a strong move higher on Monday tied to
16 December 2025
···
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is still living inside one of the more dramatic biotech story arcs of 2025: eye-popping clinical data, followed immediately by a massive equity raise, followed by a flurry of analyst price-target resets. As of Tuesday, December 16, 2025, TERN shares were trading around $44. That price level matters because it sits right on top of the two big forces investors have been digesting all month: Below is a complete, publication-ready roundup of the current news, forecasts, and market analysis shaping Terns Pharmaceuticals stock as of 16.12.2025, plus the catalysts that could drive the next move.
16 December 2025
··
Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Inc. (NYSE: PFE) heads into Tuesday, December 16, 2025 with a familiar “big pharma” cocktail of catalysts: an imminent guidance event, a high dividend yield, fresh dealmaking in hot therapeutic areas (immunology and obesity), and a regulatory backdrop that can flip sentiment faster than a lab centrifuge. Shares closed Monday at $26.43, up 2.24%, extending a four-session winning streak, according to MarketWatch. MarketWatch On the data side, Pfizer’s own calendar is the center of gravity: the company is scheduled to host an 8:00 a.m. EST analyst call today to provide full-year 2026 financial guidance. Pfizer+1 Below is what’s driving
16 December 2025
···
Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics (NASDAQ: NKTR) is in classic “biotech catalyst mode” on December 16, 2025—the kind of day when a single dataset can rewrite a stock chart in minutes. Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational candidate rezpegaldesleukin (REZPEG / NKTR-358). The company scheduled an investor call and webcast for 8:00 a.m. ET, and said the topline results would be released in a morning press release before the webcast. PR Newswire+1 By the numbers, NKTR closed
16 December 2025
··
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

December 16, 2025 — GSK plc stock (LSE: GSK; NYSE: GSK) is firmly on investors’ radar today after a cluster of late-year regulatory catalysts across respiratory, vaccines, and infectious diseases — the kind of headline flow that can reshape sentiment around a large-cap biopharma even when quarterly earnings are weeks away. In the latest available market data, GSK’s US-listed ADR (NYSE: GSK) traded around $49.24 (latest trade time in the feed: Dec. 16, 2025 00:15 UTC). Meanwhile, in London, GSK shares most recently closed at 1,833.50p on Dec. 15, up 0.49% on the day, with the Financial Times’ market data
16 December 2025
··
Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

December 15, 2025 — Merck & Co., Inc. (NYSE: MRK) traded around $99.59 in Monday afternoon action, down about 0.23% on the day, as investors balanced a fresh wave of bullish analyst updates against a busy set of catalysts spanning Winrevair, Keytruda, vaccines, and headline regulatory scrutiny. The setup for MRK stock into year-end is increasingly about “what comes after Keytruda,” and the story is getting more layered: an expanded European pathway for Winrevair (sotatercept), a higher dividend heading into the ex-dividend date, and new legal and policy crosswinds around Merck’s newer product rollouts and the U.S. vaccine environment. What’s
15 December 2025
··
AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts

AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts

AbbVie Inc. (NYSE: ABBV) stock traded higher on Monday, December 15, 2025, as investors balanced fresh analyst commentary with new exclusivity-related headlines tied to one of the company’s neuroscience brands. Shares were recently around $227, up roughly 1.7% on the session. For long-term shareholders, the bigger story remains AbbVie’s post-Humira transition: the company is leaning hard on immunology blockbusters Skyrizi and Rinvoq, while also building out oncology and neuroscience pipelines and maintaining an income-focused investor base through a growing dividend. PR Newswire+1 What’s moving AbbVie stock on Dec. 15, 2025 Two headlines stood out in Monday’s flow of AbbVie-related updates:
15 December 2025
··
Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk. On Monday, December 15, 2025, JNJ shares traded around the $214 level, brushing the upper end of their recent trading range and extending a rally that has put the healthcare bellwether sharply higher on the year. Investing.com+2MarketScreener+2 What’s moving JNJ today isn’t a single earnings surprise. Instead, it’s a high‑impact regulatory catalyst—a newly granted FDA priority voucher tied to a multiple myeloma regimen—arriving the same
15 December 2025
··
Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

December 15, 2025 — Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is getting fresh attention on Monday as the company tees up a high-visibility appearance at the J.P. Morgan Healthcare Conference early next year, while traders and analysts continue to debate the stock’s “next leg” after a strong 2025 run in rare-disease commercialization. At the same time, the backdrop around Catalyst is unusually rich with “moving parts” that matter to stockholders: a large cash position, an active share repurchase authorization, a product portfolio that’s growing (FIRDAPSE and AGAMREE) while also facing predictable generic pressure (FYCOMPA), and Wall Street price targets that still
15 December 2025
·
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

December 15, 2025 — Eli Lilly and Company (NYSE: LLY) stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the FDA review timeline for oral GLP‑1 candidate orforglipron, ongoing capacity expansion in the U.S., and a notable analyst price-target tweak hitting the tape today. MarketBeat+3Reuters+3Reuters+3 Below is what’s moving Eli Lilly stock as of 15.12.2025, what the latest forecasts imply, and which risks matter most heading into 2026. Eli Lilly stock price today: where LLY is trading on Dec. 15,
15 December 2025
··
Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis (MS) medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one of the company’s closely watched late-stage pipeline assets. Reuters+1 For U.S. investors watching the ADR, Sanofi (NASDAQ: SNY) traded around $48.68 at the latest timestamp available from market data in this session (10:15 UTC), modestly lower on the day. Below
15 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the Monday, December 15, 2025 U.S. market open with investors weighing a familiar mix: a dominant cystic fibrosis (CF) franchise that funds the story, and a fast-expanding pipeline that’s increasingly driving the debate about what Vertex should be worth next. The stock ended the last regular session (Friday, Dec. 12) at $452.04, up 1.37% on the day, extending a three-session winning streak and outperforming a down market. MarketWatch At the same time, shares remain about 13% below the 52-week high of $519.68 set in March, reflecting how much scrutiny remains on the pace
15 December 2025
··
AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 15, 2025 US market open with a familiar “big pharma” setup—steady cash returns, blockbuster execution, and a pipeline that’s increasingly being treated as a source of upside rather than a safety net. Shares last traded around $223.32, slipping modestly at Friday’s close as broader markets softened, but ABBV remains one of the stronger large-cap pharma performers in 2025. MarketWatch ABBV before the bell: the quick read What’s driving the narrative into December 15 1) Analysts are turning more constructive—and targets moved up fast Two notable Wall Street signals landed just ahead
14 December 2025
··
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Updated: Sunday, December 14, 2025 (U.S. markets last closed Friday, Dec. 12) Pfizer Inc. (NYSE: PFE) is ending the week in a familiar spot—trading in the mid‑$20s—while investors weigh a high dividend payout against a fast-moving set of catalysts: new oncology data from the Seagen portfolio, a fresh attempt at an oral obesity drug, ongoing cost-cutting, and a looming shift in the U.S. COVID vaccine policy backdrop. Reuters+3StockAnalysis+3Reuters+3 Below is a detailed roundup of the most important Pfizer stock headlines, forecasts, and analyst takes available as of Dec. 14, 2025, plus what to watch next heading into Pfizer’s scheduled 2026
14 December 2025
··
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Updated: December 14, 2025 Eli Lilly and Company (NYSE: LLY) heads into the new week with investors focused on one big theme: how far the company can extend its lead in obesity and cardiometabolic medicine while scaling supply and navigating pricing pressure. The stock’s most recent close (U.S. markets were shut Sunday) was $1,027.51. StockAnalysis Over the past two weeks, Lilly headlines have clustered around three catalysts that matter directly to the stock: Below is a detailed, publication-ready roundup of the key news, forecasts, and analyst takes driving Eli Lilly stock as of 14.12.2025. What’s moving Eli Lilly stock right
14 December 2025
··
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 (Sunday) Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: (1) the EU regulator’s support for a higher-dose Wegovy, (2) the long-telegraphed India launch of Ozempic at a sharply lower price point, and (3) the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand beyond obesity/diabetes into MASH (fatty liver disease). Reuters+2Reuters+2 While the broader 2025 narrative has been painful—Novo’s U.S. ADR is down roughly ~41% YTD by some market-data services, and Danish-listed shares have been down more than 50% at points this year—the
14 December 2025
····
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Updated: December 14, 2025Coverage window for this report: December 8–14, 2025 Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: (1) the obesity-drug arms race, (2) Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and (3) a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3 The result is a “defensive sector” that doesn’t feel defensive at all right now. The Federal Reserve’s Dec. 9–10 meeting delivered another layer
14 December 2025
······
GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

Updated: Sunday, December 14, 2025 (markets closed; prices reflect the most recent close). GSK plc (LSE: GSK / NYSE: GSK) heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion for an antibiotic, and steady buyback activity. That combination doesn’t guarantee a breakout (stocks are fickle creatures), but it does give investors a clearer map of what could move GSK shares in the days ahead. As of the latest available trading data, GSK’s U.S. ADR last traded around $48.81. In London, the most recent close was 1,824.5p (Dec. 12, 2025).
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage cardiovascular company. GlobeNewswire+1 The stock action was anything but calm. MIST closed at $2.41 on Dec. 12, down 18.31%, after swinging through a wide intraday range and printing exceptionally heavy volume. After-hours trading showed a modest rebound. StockAnalysis Below is a detailed breakdown of the latest Milestone Pharmaceuticals news, this week’s trading story, forecasts and analyst targets, and the week-ahead
14 December 2025
··
1 … 21 22 23 24 25 … 34

Stock Market Today

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

7 February 2026
London, Feb 7, 2026, 19:55 GMT — Market closed. HSBC (HSBA.L) shares ended Friday up 2.2% at 1,305.8 pence, reversing a 2.3% drop the day before, as investors steadied their views on UK rate cuts going into the new week. (Investing.com) The swing has been about the Bank of England’s split vote and what it implies for the next move. “They have tweaked the cautious easing guidance by scrapping reference to a gradual downward path of the bank rate,” said Elias Haddad, senior markets strategist at Brown Brothers Harriman. Lee Hardman, senior currency analyst at MUFG, said it “certainly looks
Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

7 February 2026
Agricultural Bank of China’s A shares closed down 0.45% at 6.67 yuan in Shanghai Friday, with turnover at 2.24 billion yuan. The bank’s A-share capital remained unchanged at 319.24 billion shares as of Jan. 31. Mainland and Hong Kong stocks fell after a global tech selloff and a sharp drop in silver futures. China’s January CPI data is due Feb. 11, with trading expected to thin ahead of the Lunar New Year break.
Palantir stock price rebounds after AI shakeout — what traders watch next week

Palantir stock price rebounds after AI shakeout — what traders watch next week

7 February 2026
Palantir Technologies shares rose 4.5% to $135.90 Friday after reporting a 70% jump in Q4 revenue to $1.407 billion and forecasting 61% revenue growth in 2026. The stock rebounded from a 6.8% drop Thursday, triggered by concerns over Big Tech capital spending and AI’s impact on software demand. A new partnership with Cognizant and U.S. government policy shifts kept Palantir in focus. Director Alexander D. Moore sold 20,000 shares on Feb. 2.
Go toTop